FDA’s OPDP Warns Insomnia Drugmaker Over Email

The US Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) sent a warning letter to Atlanta-based Galt Pharmaceuticals for an email it sent that makes false or misleading claims related to its insomnia treatment Doral (quazepam), which FDA said are “extremely concerning from a public health perspective.”